Literature DB >> 17239009

Differential expression of survivin splice isoforms in medulloblastomas.

X-N Li1, Q Shu, J M Su, A M Adesina, K K Wong, L Perlaky, B A Antalffy, S M Blaney, C C Lau.   

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is implicated in the dysregulation of apoptosis in human cancers. Survivin and survivin-deltaEx3, one of its two alternatively spliced isoforms, confer anti-apoptotic activities in human tumours, while survivin-2B antagonizes such anti-apoptotic properties. The current study was undertaken to examine the mRNA expression of survivin isoforms and their correlation with clinical staging and outcome in 20 medulloblastoma (MB) tumours, three MB cell lines and normal brain tissues (a foetal and an adult cerebellum) by densitometry scanning of 32p-dCTP incorporated reverse transcription polymerase chain reaction (RT-PCR) products and quantitative real-time PCR. Our results showed that the normal adult brain only expressed low levels of survivin-deltaEx3 mRNA, while the foetal brain expressed all three isoforms, with wild-type survivin as the dominant transcript. All three survivin isoforms were detected in all the MB cell lines and tumours analysed. Immunohistochemical staining also demonstrated survivin protein expressions in all five paraffin-embedded MBs, with predominant nuclear localization. Although overexpressions of survivin were not associated with the presence of metastatic MB or tumour histological subtypes, elevated expressions of survivin-deltaEx3 were significantly associated with progressive/recurrent tumours (P-value = 0.024). Our data demonstrated that overexpression of survivin mRNA is a common feature in MBs, may contribute to their anti-apoptosis properties and clinical behaviours, and predicts a poor clinical outcome, independent of clinical staging or tumour histology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239009     DOI: 10.1111/j.1365-2990.2006.00782.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  10 in total

1.  Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Authors:  Makito Tanaka; Marcus O Butler; Sascha Ansén; Osamu Imataki; Alla Berezovskaya; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

2.  Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.

Authors:  Tiffany Doucette; Khatri Latha; Yuhui Yang; Gregory N Fuller; Arvind Rao; Ganesh Rao
Journal:  Neuro Oncol       Date:  2014-03-27       Impact factor: 12.300

3.  Lack of prognostic significance of survivin in pediatric medulloblastoma.

Authors:  Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

4.  Subgroup-specific alternative splicing in medulloblastoma.

Authors:  Adrian M Dubuc; A Sorana Morrissy; Nanne K Kloosterhof; Paul A Northcott; Emily Py Yu; David Shih; John Peacock; Wieslawa Grajkowska; Timothy van Meter; Charles G Eberhart; Stefan Pfister; Marco A Marra; William A Weiss; Stephen W Scherer; James T Rutka; Pim J French; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2012-02-23       Impact factor: 17.088

Review 5.  Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.

Authors:  Marie-Claire Fitzgerald; Philip J O'Halloran; Niamh M C Connolly; Brona M Murphy
Journal:  Cell Death Dis       Date:  2022-05-14       Impact factor: 9.685

6.  Survivin expression in medulloblastoma: a possible marker for survival.

Authors:  Azza Abdel-Aziz; Mie Ali Ali Mohamed; Fatma Mohamed Farouk Akl; Ahmed Nageeb M Taha
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

7.  Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients.

Authors:  Maria Teresa Ionta; Maria Teresa Perra; Francesco Atzori; Cristina Maxia; Valeria Pusceddu; Paolo Demurtas; Maria Cristina Deidda; Franca Piras; Barbara Frau; Daniela Murtas; Luigi Minerba; Bruno Massidda; Paola Sirigu
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

8.  Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development.

Authors:  Francesca Menghi; Thomas S Jacques; Martino Barenco; Ed C Schwalbe; Steven C Clifford; Mike Hubank; Jonathan Ham
Journal:  Cancer Res       Date:  2011-01-19       Impact factor: 12.701

Review 9.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

10.  Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.

Authors:  S N Brun; S L Markant; L A Esparza; G Garcia; D Terry; J-M Huang; M S Pavlyukov; X-N Li; G A Grant; J R Crawford; M L Levy; E M Conway; L H Smith; I Nakano; A Berezov; M I Greene; Q Wang; R J Wechsler-Reya
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 8.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.